To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
VC-backed Metacrine goes public
San Diego-based Metacrine, a developer of therapies for patients with liver, gastrointestinal and metabolic diseases, has raised about $85 million for its IPO after pricing its 6.54 million shares at $13 per share.
